Sustained release naltrexone effective, safe for opioid users

Sustained release naltrexone effective, safe for opioid users
Sustained release technologies for administering the opioid antagonist naltrexone seem to be effective with an acceptable adverse event profile, according to a review published online Oct. 22 in the British Journal of Clinical Pharmacology.

(HealthDay)—Sustained release technologies for administering the opioid antagonist naltrexone (SRX) seem to be effective with an acceptable adverse event profile, according to a review published online Oct. 22 in the British Journal of Clinical Pharmacology.

Nikolaj Kunøe, Ph.D., from the University of Oslo in Norway, and colleagues conducted a qualitative review of the literature to provide an overview of the currently available technologies for SRX and their effectiveness in reducing opioid use.

The researchers found that the most frequently studied SRX formulations have tolerable adverse event profiles and that most studies suggest that SRX is effective at decreasing heroin use. SRX may have a protective effect on mortality and morbidity, based on registry data. In some studies, other outcomes, including concomitant substance use, vocational training attendance, needle use, and risk behavior for blood-borne diseases (including HIV and hepatitis), were also affected by SRX.

"SRX is showing promising, consistent effects in supporting ' efforts to achieve abstinence across different clinical study design and treatment settings," the authors write. "The literature on SRX for opioid addiction still requires more studies in order to confirm initial findings on effects."

One author disclosed a financial tie to Go Medical Industries, which manufactures the Australian implant.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

'Virtual bumpers' can help avoid crashes

date Sep 19, 2012

Three new Cadillac models, including the ATS sport sedan, have a new advanced safety system that can automatically stop the vehicle in low-speed conditions to help avoid crashes. 

Study sheds light on pain pill abuse

date Sep 26, 2012

A study by a team of University of Kentucky researchers has shed new light on the potential habit-forming properties of the popular pain medication tramadol, in research funded by the National Institute on Drug Abuse. The ...

Recommended for you

FDA clears drug for leading form of cystic fibrosis

date Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.